Darifenacin in the treatment of overactive bladder

Drugs of Today

Volumn 41, Issue 7, 2005, Pages 441-452

  Haab, Francois ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; CIMETIDINE; CLARITHROMYCIN; DARIFENACIN; DICYCLOVERINE; DIGOXIN; DILTIAZEM; ERYTHROMYCIN; FLAVOXATE; FLECAINIDE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEFAZODONE; NELFINAVIR; OXYBUTYNIN; PAROXETINE; PROPIVERINE; QUINIDINE; RITONAVIR; TERBINAFINE; THIORIDAZINE; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE; VERAPAMIL; WARFARIN;

ABDOMINAL PAIN; AGE DISTRIBUTION; AMNESIA; ASTHENIA; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DETRUSOR DYSSYNERGIA; DIARRHEA; DIGOXIN BLOOD LEVEL; DIZZINESS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRY EYE; DYSPEPSIA; FLU LIKE SYNDROME; HEART RATE VARIABILITY; HUMAN; INJURY; NAUSEA; NONHUMAN; OVERACTIVE BLADDER; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SALIVATION; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TORSADE DES POINTES; TREATMENT OUTCOME; URINARY TRACT INFECTION; VISUAL ACUITY; VISUAL IMPAIRMENT; XEROSTOMIA;

ANIMALS; BENZOFURANS; DRUG INTERACTIONS; HUMANS; MUSCARINIC ANTAGONISTS; PYRROLIDINES; QUALITY OF LIFE; RECEPTOR, MUSCARINIC M3; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 26844463381     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.7.891719     Document Type: Review

References (57)

1. Abrams, P., Kelleher, C.J., Kerr, L.A., Rogers, R.G. Overactive bladder significantly affects quality of life. Am J Manag Care 2000, 6(Suppl 11): S580-90.
2. Milsom, I., Abrams, P., Cardozo, L., Roberts, R.G., Thuroff, J., Wein, A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001, 87: 760-6.
3. Stewart, W.F., Van Rooyen, J.B., Cundiff, G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20: 327-36.
4. 3 muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 2002, 136: 641-4.
5. Enablex Prescribing Information 2004. Novartis Pharmaceuticals Corporation, USA.
6. Beaumont, K.C., Cussans, N.J., Nichols, D.J., Smith, D.A. Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog, and man. Xenobiotica 1998, 28: 63-75.
7. 3 receptors. J Recept Signal Transduct Res 1997, 17: 177-84.
8. Moriya, H., Takagi, Y., Nakanishi, T., Hayashi, M., Tani, T., Hitotsu, I. Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci 1999, 64: 2351-8.
9. 3 receptor subtype [abstract]. Neurourol Urodyn 2002, 21: Abst. A445.
10. 3 receptors. Eur Urol Suppl 2003, 2(1): Abst 780.
11. 3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. J Pharmacol Exp Ther 2004, 310: 1255-65.
12. 3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn-Schmiedeberg's Arch Pharmacol 2002, 366: 97-103.
13. 3 antagonist [abstract]. Pharmacol Res 1995, 31(Suppl): 54.
14. Newgreen, D.T., Naylor, A.M. Comparison of the functional muscarinic receptor selectivity of darifenacin with tolterodine and oxybutynin [abstract]. Br J Pharmacol 1996, 117(Suppl): Abst. 107P.
15. 3 antimuscarinic agent, in the anesthetised dog [abstract]. Eur Urol Suppl 2002, 1(1): 131, Abst. 515.
16. 3 selectivity [abstract]. Eur Urol Suppl 2003, 2(1): 117, Abst. 458
17. Williamson, I.J.R., Newgreen, D.T., Naylor, A.M. The effects of darifenacin and oxybutynin on bladder function and salivation in the conscious rat [abstract]. Br J Pharmacol 1997, 120(Suppl): Abst. 205P.
18. Davies, C.L., Dodd, M.G., Merner, P.A., Rankin, A.J. In vivo bladder selectivity of the novel muscarinic antagonist, darifenacin, in the conscious minipig [abstract]. Br J Pharmacol 1996, 117(Suppl): Abst. 202P.
19. Chua, C.B., Harris, D.R., Marsh, K.A., Hill, S.J., Bates, C.P. Effect of darifenacin on muscarinic responses in normal and unstable human detrusor smooth muscle cells [abstract]. Neurourol Urodyn 1997, 16: 355-6, Abst. 9a.
20. Yoshida, M., Miyamae, K., Murakami, S., Yono, M., Inadome, A., Ueda, S. Comparison of pharmacological effects on various antimuscarinic drugs on human isolated urinary bladder [abstract]. Neurourol Urodyn 2001, 20: 462-3, Abst. 57.
21. Miyamae, K., Yoshida, M., Murakami, S., et al. Pharmacological effects of darifenacin on human isolated urinary bladder. Pharmacology 2003, 69: 205-11.
22. Skerjanec, A., Devineni, D. Affinity of darifenacin for the p-glycoprotein efflux pump: a mechanism contributing to the CNS sparing profile? [abstract]. British Pharmacological Society Winter Meeting December 14-16, 2004, Newcastle UK.
23. Kerbusch, T., Wählby, U., Milligan, P.A., Karlsson, M.O. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol 2003, 56: 639-52.
24. Nichols, D.J. No effect of food on pharmacokinetics of darifenacin in multiple doses [abstract]. Pharmacol Toxicol 2001, 89 (Suppl 1): 89, Abst. 346.
25. 3 selective receptor antagonist: effects of renal or hepatic impairment [abstract]. Proceedings of the British Pharmacological Society, Newcastle, UK, Winter 2004 at http://www. pa2 online.org/ vol2issue4abst157p.html.
26. Emselex Summary of Product Characteristics (SmPC). Novartis Europharm Limited, UK, October 2004. Available from the European Medicines Agency (EMEA): http://www.emea. eu.int/humandocs/Humans/EPAR/emselex/emse elex.htm.
27. Salvatore, S. Darifenacin does not affect the pharmacokinetics of a combined oral contraceptive (Microgynon®) in healthy women [abstract]. Int Urogynecol J 2001, 12(Suppl 3): S32, Abst. 49(268).
28. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004, 45: 420-9.
29. 3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 2005, in press.
30. 3 selective receptor antagonist. BJU Int 2005, 95: 580-6, erratum 2005, 95: 1385-6.
31. Emselex European Public Assessment Report (EPAR). Scientific Discussion. European Medicines Agency (EMEA), http://www.emea.eu. int/humandocs/Humans/EPAR/ emselex/emse lex.htm.
32. Chapple, C.R., Steers, W., Norton, P., et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005, 95: 993-1001.
33. Abrams, P., Larsson, G., Chapple, C., Wein, A.J. Factors involved in the success of anti-muscarinic treatment. BJU Int 1999, 83(Suppl 2): 42-7.
34. Quinn, P., Goka, J., Richardson, H. Assessment of an electronic daily diary in patients with overactive bladder. BJU Int 2003, 91: 647-52.
35. Abrams, P., Lheritier, K., Steel, M. Approaches for determining the efficacy of treatment for overactive bladder: assessment of responder rates to darifenacin in a pooled analysis of phase III studies [abstract]. Eur Urol Suppl 2005, 4: 142(Abst. 558).
36. Abrams, P., Foote, J., Lheritier, K. Urinary continence during darifenacin therapy for overactive bladder (overactive bladder): pooled data from phase III trials [abstract]. Eur Urol Suppl 2005, 4: 60 (Abst. 229).
37. Abrams, P., Foote, J., Lheritier, K., Steel, M. Responder rates, a better way to express drug efficacy: data from darifenacin pooled phase III studies [abstract]. 34th Annual Meeting of the International Continence Society (August 25-27, Paris, France) 2004, Abst. 389 http://www. continet. org/publications/ 2004/pdf/0389.pdf.
38. 3 antagonist for overactive bladder: comparison with oxybutynin on ambulatory urodynamic monitoring and salivary flow [abstract]. 31st Annual Meeting of the International Continence Society (September 18-21, Seoul, South Korea) 2001, Abst 221. http://www.continet.org/publications/2001/ pdf/0221.pdf.
39. 3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005, in press.
40. 3 selective receptor antagonist, compared with oxybutynin in the treatment of patients with overactive bladder [abstract]. 34th Annual Meeting of the International Continence Society, (August 25-27, Paris, France) 2004, Abst. 378 http://www. continet.org/publications/2004/pdf/ 0378.pdf.
41. Beers, M.H. Explicit criteria for determining potentially inappropriate medication use by the elderly. Arch Intern Med 1997, 157: 1531-6.
42. Pick, D.M., Cooper, J.W., Wade, W.E., Waller, J.L., Maclean, J.R., Beers, M.H. Updating the Beers Criteria for potentially inappropriate medication use in older adults. Arch Intern Med 2003, 163: 2716-24.
43. 3 selective receptor antagonist. Eur Urol 2005, in press.
44. Kelleher, C.J., Cardozo, L.D., Khullar, V., Salvatore, S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997, 104: 1374-9.
45. Reese, P.R., Pleil, A.M., Okano, G.J., Kelleher, C.J. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res 2003, 12: 427-42.
46. 3 selective receptor antagonist, in patients with overactive bladder [abstract]. BJU Int 2004, 94(Suppl 2): Abst. 1136.
47. Steel, M., Kahler, K. Patient perceived quality of treatment is a valid method to assess the satisfaction, preference and willingness of patients to re-use treatment for overactive bladder [abstract]. Prog Urol 2004, 14(Suppl 3): 23, Abst. 69.
48. Glavind, K., Perrault, L. Patient satisfaction, preference, and willingness to reuse darifenacin in the treatment of overactive bladder [abstract]. BJU Int 2004, 94(Suppl 2): Abst. 1139.
49. Abrams, P., Steel, M., Ebinger, U. Darifenacin versus oxybutynin for overactive bladder (OAB) [abstract]. WONCA/AAFP meeting (October 13-17, Orlando, USA) 2004, Abst./Poster 4029.
50. Foote, J., Glavind, K., Kay, G. Central nervous system (CNS)-related adverse events in patients with overactive bladder (overactive bladder) treated with darifenacin versus tolterodine [abstract]. BJU Int 2004, 94(Suppl 2): Abst. 1134.
51. 3 receptor selectivity. Eur Urol Suppl 2002, 1 (Suppl): 23-8.
52. Donnellan, C.A., Fook, L., McDonald, P., Playfer, J.R. Oxybutynin and cognitive dysfunction. BMJ 1997, 315: 1363-4.
53. Womack, K.B., Heilman, K.M. Tolterodine and memory: dry but forgetful. Arch Neurol 2003, 60: 771-3.
54. Kay, G., Wesnes, K. Pharmacodynamic effects of darifenacin, a muscarinic receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 2005, in press.
55. Lipton, R.B., Kolodner, K., Wesnes, K. Assessment of cognitive function in the elderly population: effects of darifenacin. J Urol 2005, 173: 493-8.
56. 1 muscarinic acetylcholine receptors in rat ventricular myocytes. Circ Res 1996, 79: 86-93.
57. 3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharm 2005, 45: 1038-47.